Allogeneic bone marrow transplantation in a patient with T-prolymphocytic leukemia with small-intestinal involvement.
Although T-prolymphocytic leukemia (T-PLL) is characterized by organ infiltration, small-intestinal involvement is rare. We performed an unrelated allogeneic bone marrow transplantation in a patient with T-PLL who had multiple lymphomatous polyposis of the small intestine refractory to combination chemotherapy (cyclophosphamide, vincristine, and prednisolone [COP] and fludarabine plus cyclophosphamide). The patient developed no graft-versus-host disease (GVHD) and remains in complete remission 16 months after the transplantation. T-PLL is usually refractory to chemotherapy and is a T-cell malignancy with poor prognosis. There have been several reports on allogeneic hematopoietic stem-cell transplantation (allo-HSCT) for T-PLL, but none on allo-HSCT for T-PLL patients with intestinal involvement. It is suggested that allo-HSCT may improve the prognosis in patients with T-PLL involving the small intestine.
Murase
Kazuyuki
K
Fourth Department of Internal Medicine, Sapporo Medical University, S1W17, Chuo-ku, Sapporo 060-8543, Japan.
Matsunaga
Takuya
T
Sato
Tsutomu
T
Kuribayashi
Kageaki
K
Kogawa
Katsuhisa
K
Kawano
Yutaka
Y
Okamoto
Tetsuro
T
Takayama
Tetsuji
T
Watanabe
Hideki
H
Niitsu
Yoshiro
Y
Hirayama
Yasuo
Y
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003520:Cyclophosphamide / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D006801:Humans; D044483:Intestinal Polyposis / Q000209:etiology* / Q000473:pathology; D015463:Leukemia, Prolymphocytic / Q000150:complications* / Q000628:therapy*; D015458:Leukemia, T-Cell / Q000150:complications* / Q000628:therapy*; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine; D011241:Prednisone